Compare NUVL & PL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | PL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.0B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | PL |
|---|---|---|
| Price | $100.82 | $22.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $135.00 | $17.10 |
| AVG Volume (30 Days) | 497.6K | ★ 13.4M |
| Earning Date | 02-27-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $282,459,000.00 |
| Revenue This Year | N/A | $26.28 |
| Revenue Next Year | N/A | $26.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.89 |
| 52 Week Low | $55.54 | $2.79 |
| 52 Week High | $113.02 | $30.90 |
| Indicator | NUVL | PL |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 44.39 |
| Support Level | $98.65 | $19.98 |
| Resistance Level | $106.57 | $24.10 |
| Average True Range (ATR) | 4.46 | 2.05 |
| MACD | -0.29 | -0.70 |
| Stochastic Oscillator | 47.36 | 15.02 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Planet Labs PBC is an Earth-imaging company. It uses space to help life on Earth by imaging the world every day and making change visible, accessible, and actionable. Its platform includes imagery, insights, and machine learning that empower companies, governments, and communities around the world to make timely decisions about the evolving world. Its solutions are Broad Area Management. Its products are Planet Monitoring, Planet Tasking, Planet Analytic Feeds, Planetary Variables, Planet Basemaps, Planet Insights, and Platform Pricing. The group provides solutions to the Agriculture Science Program, Energy & Infrastructure, Forestry & Land Use, Mapping, Sustainability, Maritime, Civil Government, U.S. State and Local, Europe, Planet Federal, Defense & Intelligence, and Armed Services.